A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Titel:
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Auteur:
Sanchorawala, Vaishali Palladini, Giovanni Kukreti, Vishal Zonder, Jeffrey A. Cohen, Adam D. Seldin, David C. Dispenzieri, Angela Jaccard, Arnaud Schönland, Stefan O. Berg, Deborah Yang, Huyuan Gupta, Neeraj Hui, Ai-Min Comenzo, Raymond L. Merlini, Giampaolo